CCT301 38

Drug Profile

CCT301 38

Alternative Names: CCT301-38

Latest Information Update: 19 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioAtla
  • Developer Shanghai Sinobioway Sunterra Biotechnology
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Renal cell carcinoma

Most Recent Events

  • 08 Jan 2018 Shanghai Sinobioway Sunterra Biotechnology receives ethics committee approval of a clinical trial for CCT301-38 and CCT301-59 for the treatment of Renal cell carcinoma in China
  • 08 Jan 2018 BioAtla in collaboration with F1 Oncology and Shanghai Sinobioway Sunterra Biotechnology plans a clinical trial of CCT301 38 and CCT301 59 for Renal cell carcinoma (Second-line therapy or greater, Late-stage disease, Metastatic disease) in China
  • 01 Jan 2018 Phase-I/II clinical trials in Renal cell carcinoma (Recurrent, Second-line therapy or greater, Metastatic disease, Late stage disease) in China (IV) (NCT03393936)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top